


The
Patent
Office

PCT/GB 92 / 01892

11 November 1992



The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

#2
08 JUN 1994

I, the undersigned, being an officer duly authorised in accordance with Section 62(3) of the Patents and Designs Act 1907, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the Patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

PRIORITY DOCUMENT

BEST AVAILABLE COPY

Signed

A.W. Russell

Dated

- 4 NOV 1992

THIS PAGE BLANK (USPTO)

£25

official use



07 OCT 1992 77 UC 25.00

9221094.7
9221094.7

Your reference
SGH

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-438 4700).

Rule 16 of the Patents Rules 1990 the main rule governing the completion and filing of this form.

Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.



Request for grant of a Patent

Form 1/77

Patents Act 1977

1 Title of invention

1 Please give the title of the invention Binding assay employing labelled reagent

2 Applicant's details

☐ **First or only applicant**

2a If you are applying as a corporate body please give:
Corporate name Multilyte Limited

Country (and State of incorporation, if appropriate) United Kingdom

2b If you are applying as an individual or one of a partnership please give in full:

Surname
Forenames

2c In all cases, please give the following details:

Address M J Ventham & Co.,
Kingsbourne House,
229-231 High Holborn
London

UK postcode (if applicable) WC1V 7DA

Country United Kingdom

ADP number (if known) 6207864001

RP

2d, 2e and 2f: If there are further applicants please provide details on a separate sheet of paper.

☐ **Second applicant (if any)**

2d If you are applying as a corporate body please give:

Corporate name

Country (and State
of incorporation, if
appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2f **In all cases**, please give the following details:

Address

UK postcode
(if applicable)

Country

ADP number
(if known)

Ⓜ An address for service in the United Kingdom must be supplied

Please mark correct box

Ⓜ **Address for service details**

3a Have you appointed an agent to deal with your application?

Yes ☒ No ☐ → go to 3b

↓
please give details below

Agent's name J.Y. & G.W. JOHNSON

Agent's address Furnival House,
14-18 High Holborn,
London,

Postcode WC1V 6DE

Agent's ADP number 976001

3b: If you have appointed an agent, all correspondence concerning your application will be sent to the agent's United Kingdom address.

3b If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode

ADP number
(if known)

Daytime telephone
number (if available)

④ Reference number

4 Agent's or
applicant's reference number (if applicable) SGH - Case 10A

⑤ Claiming an earlier application date

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Yes ☐ No ☒ → go to 6

↓
please give details below

☐ number of earlier
application or patent
number

☐ filing date
(day month year)

☐ and the Section of the Patents Act 1977 under which you are claiming:

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

⑥ Declaration of priority

6 If you are declaring priority from previous application(s), please give:

Country of filing	Priority application number (if known)	Filing date (day, month, year)
-------------------	---	-----------------------------------

GB

9121873.5

15.10.1991

Please mark correct box

Please mark correct box

⑥ If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

Please give the date in all number format, for example, 31/05/90 for 31 May 1990.

- ⑦ The answer must be 'No' if:
- any applicant is not an inventor
 - there is an inventor who is not an applicant, or
 - any applicant is a corporate body.

⑧ Please supply duplicates of claim(s), abstract, description and drawing(s).

Please mark correct box(es)

- ⑨ You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here ➡

A completed fee sheet should preferably accompany the fee.

7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark correct box

Yes ☐

No ☒

A Statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77

Claim(s)

5

Description

34

Abstract

Drawing(s)

3

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 – Statement of Inventorship and Right to Grant
(please state how many)

Patents Form 9/77 – Preliminary Examination/Search

Patents Form 10/77 – Request for Substantive Examination

9 Request

I/We request the grant of a patent on the basis of this application.

Signed

Date 07 October 1992
(day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either:

☐ **The Comptroller
The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH**

or

☐ **The Comptroller
The Patent Office
25 Southampton Buildings
London
WC2A 1AY**

Binding assay employing labelled reagent

The present invention relates to binding assays employing a labelled reagent. Binding assays include immunoassays for the determination of concentrations of
5 antigens in liquid samples, and it is also possible to use the present invention for the determination or detection of other analytes in liquid samples, including DNA sequences.

The present invention has particular relevance to non-competitive sandwich assays, that is to say assays in which
10 a liquid sample containing an antigen or other analyte to be assayed such as a hormone is contacted with a first binding agent (such as an antibody) having binding sites on its molecule specific for the analyte whereby a fraction of the binding sites on the first binding agent representative of
15 the concentration of the analyte in the liquid sample are occupied by the analyte. The fractional occupancy of the binding sites is then determined by a back-titration technique involving the use of a second binding material which is capable of binding with the bound analyte or with
20 the binding sites occupied by bound analyte but not with unoccupied binding sites. Conveniently, the first binding agent will be referred to hereinafter as the capture binding agent and the second binding material will be referred to hereinafter as the developing binding material.

25 Non-competitive assays are to be distinguished from competitive assays in which the back-titration technique involves the use of a developing binding material which competes with the analyte for the binding sites on the capture binding agent, for example a labelled version of the
30 analyte or another material able to bind with the unoccupied binding sites on the capture binding agent, although the present invention can also be used in such assays. In each case the extent of binding of the developing binding material is determined by the labelling of the developing
35 binding material (or both that material and the capture

binding agent), for example with a fluorescent label, and comparing the strength of the signal emitted by the bound labelled product of analyte bound to capture binding agent and developing binding material in the case of the unknown
5 sample with the signal strengths achieved with corresponding samples of known analyte concentration which together provide a dose-response curve. One type of non-competitive sandwich assay involves the use of a labelled developing binding material and an immobilised capture binding agent
10 which may or may not be labelled.

It is now well-recognised that non-competitive sandwich immunoassays generally display higher sensitivity than the more conventional competitive immunoassays. The widely accepted explanation for this higher sensitivity is
15 the use of relatively large amounts both of the immobilised capture binding agent (usually an antibody located on a solid support) and of the labelled developing binding material (also often an antibody). By using large amounts of the antibodies, especially the capture antibody, the rate
20 of reaction between analyte and capture antibody is increased, implying in accordance with the law of mass action that a greater amount of analyte is captured on the solid phase capture antibody in any specified time interval. Thus, the use of large amounts of capture antibody is
25 generally perceived as crucial to the development of non-competitive immunoassays combining very high sensitivity with relatively short incubation times. (See for example Hay et al. "American Thyroid Association Assessment of Current Free Thyroid Hormone and Thyrotropin Measurements
30 and Guidelines for Future Clinical Assays" in Clinical Chemistry, Vol 37, No. 11, (1991) at pages 2002-2008.) This approach nevertheless carries disadvantages. For example, it implies heavy consumption of antibodies which may be scarce and costly to produce. It also involves the use of
35 various stratagems to maximise the total surface area of the solid support on which the capture antibody is deposited. For example, porous glass microspheres have been used as a

solid support in sandwich assay systems, the pores greatly increasing the surface area available for antibody attachment.

Roger Ekins has previously argued, for example in
5 WO-84/01031, WO-88/01058 and WO-89/01157, that this general
perception is mistaken and that, in certain circumstances,
assays which are even more sensitive than those attainable
under the conditions mentioned above are obtainable when and
only when the unknown sample and standard samples containing
10 the analyte are each contacted with such a small amount of
the capture binding agent that only an insignificant
fraction of the analyte becomes bound to the capture binding
agent. (This insignificant fraction is usually less than 5%
and ideally 1-2% or less, bearing in mind that errors in
15 analyte determination unavoidably introduced into the
measuring procedure elsewhere by limitations in the accuracy
of sample and reagent manipulation, signal measurements,
standardisation, temperature variation and the like are
generally of the order of 10% or less of the analyte in the
20 sample, although sometimes higher fractions up to 10% or so
may be tolerated when exact accuracy is less important.)
Only in such circumstances is the fractional occupancy F of
the binding sites on the capture binding agent related to
the concentration [A] of analyte in the sample (at
25 thermodynamic equilibrium) by the equation

$$F = \frac{K[A]}{1 + K[A]}$$

where K is the affinity constant of the capture binding
agent for the analyte and is a constant at a given
30 temperature and other given conditions. Before
thermodynamic equilibrium is reached, the above equation
also approximately applies (provided that only an
insignificant fraction of the analyte in the sample has
become bound to the capture binding agent at the time of
35 measurement, irrespective of whether a higher, significant

amount becomes bound subsequently, for example when equilibrium is reached), subject only to the alteration that in such a situation the constant K in the equation is the apparent affinity constant of the capture binding agent for
5 the analyte at the time of measurement.

It has also been proposed by Roger Ekins in WO-89/01157 etc to carry out such a technique using the capture binding agent spotted onto a solid support in the form of one or more microspots, for example with diameters of 1 mm²
10 or less, using sample volumes of the order of 1 ml or less.

However, with such a system a problem may arise to provide a label which can give a sufficiently strong but sensitive signal. Doubts have also been expressed regarding sensitivities attainable using microspot assay formats on
15 the ground that the use of very small amounts of solid-phase capture binding agent must intrinsically necessitate long incubation times and yield low sensitivity.

We have now found that in such a system very good results can be obtained by using as the labelling system
20 micron or preferably sub-micron sized microspheres carrying a marker, preferably a fluorescent label. By combining the use of such a label for the developing binding material alone or for both the developing binding material and the capture binding agent with very small amounts of capture
25 binding agent located at a high surface density on a solid support in the form of a microspot, non-competitive assay systems may be devised which are as rapid to perform as or even more rapid to perform than, and possess sensitivities comparable with or indeed greatly superior to, those of
30 conventional sandwich systems relying upon comparatively large amounts of capture binding agent. This crucial finding, which contradicts currently accepted views on the design of high sensitivity assays and is totally unexpected, potentially forms the basis of development of a variety of
35 superior miniaturized diagnostic devices possessing

exceedingly high sensitivity whilst requiring only relatively short incubation and measurement times.

Of course, the microspheres can also be used for labelling purposes in a competitive assay system using
5 similarly very small amounts of capture binding agent, but corresponding or substantial increases in sensitivity due to their use would not necessarily be achieved or even expected, although increases in rapidity can be expected.

According to the present invention there is provided
10 a binding assay process in which the concentration of an analyte in a liquid sample is determined by comparison with a dose-response curve computed from standard samples, using a capture binding agent having binding sites specific for the analyte and a developing binding material capable of
15 binding with the bound analyte or with the binding sites on the capture binding agent occupied by the bound analyte or with the binding sites remaining unoccupied on the capture binding agent, the capture binding agent being used in an amount such that only an insignificant fraction of the
20 analyte in the sample becomes bound to the capture binding agent, and a label being used in the assay in relation to the developing binding material whereby the strength of the signal associated with the label is representative of the fractional occupancy of the binding sites on the capture
25 binding agent by the analyte, in which process there is used as the label microspheres having a size of less than 5 μm and carrying a marker, preferably a fluorescent label.

Fluorescent microspheres of micron and submicron size have been known since about 1982 and are commercially
30 available from many sources, e.g. under the trade mark FluoSpheres from Molecular Probes Inc.. Suitable microspheres have a diameter of generally less than 5 μm and preferably not more than 1 μm , more preferably of the order of 0.01 to 0.5 μm , and it is preferred to use spheres all
35 essentially of the same standard size. The microspheres may

be made of any suitable or convenient inert material such as a polymer latex, for example a polystyrene latex, which is desirably provided on its surface with either negatively charged groups such as sulphate, carboxyl or carboxylate-
5 modified groups or positively charged groups such as amidine groups. The presence of such charged groups on the surface of the spheres allows a wide variety of proteins, such as IgG, avidin/streptavidin and BSA, to be adsorbed passively on or coupled covalently to the surfaces of the spheres at
10 various surface densities as desired.

Although the microspheres may carry markers of various types, for example radioactive or chemiluminescent labels, they preferably carry fluorescent labels. These labels are preferably contained within the microspheres. Each
15 microsphere desirably contains large numbers of fluorescent dye molecules as labels, for example up to 10 million in 1 μ m diameter spheres with smaller numbers in smaller spheres (e.g. 100 or 1,000 to 100,000 or 1 million) down to about 10 in very small spheres. The fluorescent dye molecules may be
20 selected to provide fluorescence of the appropriate colour range (excitation and emission wavelength) compatible with standard filter sets, for example yellow/green, orange or red, or customised filter sets may be used. Fluorescent dyes include coumarin, fluorescein, rhodamine and Texas
25 Red. The fluorescent dye molecules may be ones having a prolonged fluorescent period such that the strength of the signal emitted by them can be determined by the known time-resolved fluorescence technique after background interference has decayed, for example lanthanide chelates
30 and cryptates. Dyes which fluoresce only in non-aqueous media can be used. Preferred fluorescent dyes for use in the microspheres are oil-soluble dyes in order to facilitate their incorporation into the interior of the microspheres. Yellow/green, orange and red FluoSpheres, which are excited
35 very efficiently at the 488, 568 and 647 nm krypton/argon mixed gas laser lines, respectively, are presently preferred.

In use as the label for the developing binding material, or for the capture binding agent and the developing binding material, in the assay systems of the invention the microspheres may have the developing binding material, or avidin which can be used as a "universal marker" reagent and bind all biotinylated binding material, or the capture binding agent as the case may be, physically adsorbed onto the surface of the spheres. More conveniently, however, appropriately surface-modified microspheres are selected and the developing binding material (eg. antibody) or capture binding agent (eg. antibody) is covalently bonded to them either directly or through a linking grouping, such as is provided by carbodiimide activation. Thus, for example, to link the microspheres and binding material the binding material may be adsorbed onto hydrophobic sulphate-modified microspheres or covalently coupled to aldehyde-modified or carboxylate-modified hydrophilic microspheres, the latter via a water-soluble carbodiimide. When both the capture binding agent and the developing binding material are labelled with fluorescent microspheres, different dyes will of course be used in the two sets of microspheres.

It will be apparent therefore that the microspheres containing many molecules of a fluorescent dye provide an amplification system in the sense that one molecule or unit of the developing binding material gives rise to a signal which is due to large number of fluorescent dye molecules. Such an amplification system is thus able greatly to increase the sensitivity of these assay procedures in which the controlling factor in assay sensitivity is signal magnitude, for example when only a very small amount of capture binding agent is used and hence the amount of developing binding material is also very small.

The microspheres are primarily used in conjunction with an assay system in which the immobilised material, usually the capture binding agent (capture antibody), is deposited

on a solid support in the form of one or more microspots having an area of 1 mm^2 down to $100 \text{ } \mu\text{m}^2$ or less, for example a diameter of 0.01-1 mm, although for very small microspots it may be necessary to use very small microspheres or fewer
5 larger microspheres. The surface density of the capture binding agent on the microspot is desirably in the range 1,000 to 100,000 IgG molecules/ μm^2 , preferably 10,000 to 50,000 IgG molecules/ μm^2 . These microspots are used in conjunction with sample sizes of 1 ml or less, for example
10 down to 50 or 100 μl or even less depending on the size of the microspot, the aim being to cover the microspot.

The microspot technique can be used to determine different analytes in the same or different liquid samples in a single operation by immobilising different capture
15 binding agents on different microspots on the same solid support and using different or identical developing binding materials labelled with the microspheres for the different binding assays. The labels (fluorescent dyes) associated with different binding assays and/or the techniques used to
20 measure the signal strengths will be chosen to enable the results from the different assays to be differentiated. Techniques for this are known, for example from WO-88/01058.

To optimise the results achievable with the present invention a number of different features should be
25 optimised, including the following:-

- i) the fractional occupancy of the capture binding agent by the analyte,
- ii) the size of the affinity constant of the capture binding agent for the analyte at the time when
30 measurement occurs and, if the measurement is to be performed before equilibrium has been reached, the rate at which equilibrium is reached,
- iii) the surface density of the capture binding agent on its support,
- 35 iv) the size of the microspots,

- v) the nature of the support,
- vi) the instrument used to measure the signal,
- vii) the treatment of the microspheres, for example to block unreacted sites, and
- 5 viii) the nature of the buffer solutions used.

For feature 1) it should be noted that the use of too much capture binding agent is to be avoided for optimal sensitivity. It is theoretically demonstrable that the highest signal/noise ratio (R) is obtained (assuming the
10 measuring instrument itself generates zero noise) when the amount of capture binding agent falls below $0.01/K$ and approaches zero, K being the affinity constant between the capture binding agent and the analyte at the time of measurement. Let us define this signal/noise ratio as R_0 .
15 (Note that an amount of capture binding agent of $0.01/K$ binds $< 1\%$ of analyte molecules present in the solution - assumed to be very small - to which the capture binding agent is exposed.) If the area on which the capture binding agent is deposited is increased (the surface density of
20 binding agent remaining constant) the amount of binding agent will concomitantly increase. The percentage of total analyte bound will also increase (albeit to a lesser proportional extent) but the signal/noise ratio will decrease. For example, if the area is increased 100-fold so
25 that the amount of binding agent equals $1/K$, the amount of analyte bound will rise to $< 50\%$, and the signal/ noise ratio will fall to $R_0/2$.

The relationship between the ratio R and capture binding agent concentration (ie area coated with binding
30 agent) is shown in Figure 1 of the accompanying drawings. This Figure is a graph of the signal/noise ratio (the continuous line where the y-axis is % of the value when the area coated with binding agent, and hence the binding agent concentration, approaches zero) and the amount of bound
35 analyte (the dashed line, where the y-axis is % of total analyte present in the medium, assuming the total amount of

analyte is very low, ie $<0.0001/K$) as functions of the total amount of capture binding agent (in units of $1/K$, the x-axis) on the coated area. Clearly, as the area coated with capture binding agent (and hence its concentration) increases, the percentage of total analyte bound increases, but the signal/noise ratio falls. This effect is shown pictorially in Figure 2 of the accompanying drawings, where d is the diameter in mm of the area coated with capture binding agent, $[Ab]$ is the concentration of binding agent assuming a surface density of $0.1/K$ per mm^2 , and s/n is the signal/noise ratio expressed as a percentage of the value observed as the surface area approaches zero. This Figure likewise endeavours to show that, as the coated area increases, the amount of analyte bound also increases but the signal/noise ratio and hence the sensitivity fall.

However, although the signal/noise ratio R is highest when the binding agent concentration is less than $0.01/K$, it is clear that the ratio is still acceptably high when the amount of capture binding agent used equals and even exceeds $1/K$. The upper limit to the amount of binding agent coated on the area is preferably $10/K$. This implies a ten-fold lower sensitivity than is achievable using a 1000-fold lower amount of binding agent and it should be emphasized that, although the invention is capable of yielding very high sensitivity, it is also applicable where lower sensitivity than the maximum attainable is acceptable.

For factor ii) it should be noted that, although at first sight it might appear that better results would be achieved by the use of a capture binding agent with a low value of K , it is in fact found that it is better to use a higher value of K , e.g. $10^{11} - 10^{12}$ litres/mole, and to make the measurement before equilibrium has been reached so that at the moment of measurement only an insignificant fraction of the analyte has become bound, even though a substantial fraction might become bound if measurement were to be delayed until equilibrium had been reached. It is preferred

to use a capture binding agent such that, in the amounts used, equilibrium is reached within 12 hours or somewhat less but to make the measurement within about 2 hours or less, well before equilibrium is reached. This early pre-
5 equilibrium measurement is particularly important where the capture binding agent has a very high affinity constant for the analyte, as is the case with DNA probes.

For factor iii) it should be noted that too low a surface density decreases the signal/noise ratio because the
10 area occupied by the capture binding agent and scanned to determine the ratio increases. On the other hand too high a surface density can cause steric hindrance between adjacent capture binding agent molecules so that not all the molecules are available for binding the analyte.
15 Preliminary experiments to see if steric hindrance is a problem can be carried out by making spots of varying binding agent surface density, labelling them with a label such as I^{125} and measuring how the signal varies with binding agent surface density, the optimum being the highest
20 signal. In the past conventional practice has been to use coatings of the order of 10 μg of capture binding agent per ml but for the present invention figures of 100-200 μg of capture binding agent per ml may be more appropriate. The use of higher surface density also has the advantage that
25 less of the surface is available for non-specific binding, which would otherwise increase the noise and reduce the signal/noise ratio.

For factor v) it should be noted that the background used will contribute to the noise. It may be preferable to
30 use a black background rather than a white one.

For factor vi) it is preferred that the area illuminated for the purposes of determining the signal/noise ratio should be as small as possible, preferably limited to the microspot or a portion of it. Scanning a wider area
35 increases the noise level and thus decreases the

signal/noise ratio. Hence it is desirable to concentrate the illumination and to scan by means of a confocal microscope or other instrument achieving very precise illumination and measurement.

5 For factor vii) it is to be noted that it is possible to use either adsorption or covalent linking of the developing binding material or capture binding agent to the microspheres. However, non-specific binding should be avoided. Accordingly, after either adsorption or covalent
10 bonding with the developing binding material or capture binding agent has been carried out, the unreacted sites on the microspheres are desirably blocked to avoid their non-specific binding to other biological molecules or the receptor support. Blocking may be carried out with any non-
15 interfering protein material. An albumin, particularly bovine serum albumin, is preferred. It has been found desirable to block not only with bovine serum albumin (BSA) or equivalent but also with a detergent such as TWEEN-20 or other non-ionic detergent. It is believed that there are
20 some binding sites on the microspheres which are not blocked by BSA alone. Microspheres blocked with BSA alone appear have binding sites which are capable of binding to the solid support, such as the plastic walls of the microtitre wells in which the assay is performed, or to other biological or
25 non-biological molecules such as are present in other components of the system (eg the liquid sample), as well as being capable of non-specific binding to the capture binding agent. Use of a detergent as additional blocking agent decreases the number of such binding sites or eliminates
30 them altogether. The detergent also helps to remove loosely bound capture binding agent or other proteins which might desorb into storage buffer and/or assay buffer and interfere with assays. Non-interfering reactants can be used to block activated groups on the surface of the
35 microspheres, for example inert amines such as ethanolamine, glycine or lysine to block activated carboxyl groups, but any particular compounds should be checked for assay

compatibility.

For factor viii) it should be noted that the choice of ingredients for the assay buffer and the wash buffer can influence the sensitivity of the results. With TSH, for example, TRIS gives a better buffer than phosphate. It may also be desirable to include a detergent such as TWEEN 40 to reduce non-specific binding.

In other respects the immunoassay may be carried out in a known manner, for example as described in Roger Ekins' earlier patent applications as mentioned above, and incorporated herein by reference, or in the other literature. When carrying out immunoassays it is preferred, although not essential, for both the capture binding agent and the developing binding material to be antibodies. Monoclonal or polyclonal antibodies may be used and the procedure may be used to assay analytes such as hormones, nucleic acid, proteins, vitamins, drugs, viruses, bacteria, pesticides, tumour markers or other components of biological samples such as body fluids, the capture binding agent and developing binding material being appropriately chosen so as to bind to the analyte in question. The analyte can be a nucleotide sequence, eg a DNA oligonucleotide sequence in which case the capture binding agent and the developing binding material may both be other nucleotide sequences, which will differ from one another. The analyte may contain only one epitope for the capture binding agent or the epitope may be replicated on the analyte molecule. The polyclonal developing binding material (antibody) may react with a variety of epitopes on the analyte or the analyte capture binding agent complex, or a mixture of two or more monoclonal developing binding materials (antibodies) reacting with different epitopes may be used.

When used for nucleic acid (DNA) assays the DNA probe, a single-stranded nucleotide sequence, eg an oligonucleotide sequence of conventional or standard type, is attached as

capture binding agent to a solid support and this recognises a corresponding single-standard DNA sequence constituting the analyte in a liquid sample and such sequences become bound so as to form a twin-stranded sequence. The
5 developing binding material may be either a labelled antibody which recognises the twin-stranded sequence as opposed to single-stranded sequences or another DNA sequence which recognises another part of the DNA sequence constituting the analyte and is labelled, both these binding
10 materials producing non-competitive assays. For competitive assays it is possible to use a labelled developing binding material recognising unoccupied sites of the capture binding agent, ie residual DNA probe not bound to analyte. In each case the label is provided in accordance with the invention
15 by the microspheres carrying a marker, preferably molecules of a fluorescent dye contained within the microspheres.

DNA assays according to the present invention therefore provide an alternative to the well-known polymerase chain reaction (PCR) for assaying DNA sequences.
20 The PCR method is subject to certain disadvantages, including errors introduced by repeated cycles of amplification (doubling) on an initial very low concentration of DNA sequence. The present invention provides an alternative enhancement procedure in which an
25 initial very low concentration of the DNA sequence to be detected or determined gives rise to an amplified signal in a single step because of the large number of fluorescent dye molecules contained within the microsphere to which a molecule of the developing binding material (antibody or
30 other DNA sequence) is attached as by adsorption or direct or indirect chemical bonding.

According to a further embodiment of the invention there is provided a binding assay process for the detection of an analyte comprising single-stranded DNA sequence in a
35 liquid sample, the process comprising contacting the sample in a non-competitive or competitive procedure with an

immobilised capture binding agent which is a single-stranded oligonucleotide DNA probe capable of recognising analyte in the liquid sample and binding therewith, and with a labelled developing binding material which either is an antibody
5 capable of recognising only twin-stranded DNA sequences formed from the probe and the analyte and of binding therewith or is an oligonucleotide DNA sequence capable of recognising and binding with either another part of the analyte or the residual probe, the developing binding
10 material being labelled by means of microspheres having a size of less than 5 μm and carrying a marker, and, after the removal of unattached developing binding material, detecting the presence of the analyte by the existence or strength of a signal from the marker attached to developing binding
15 material which has become bonded directly or indirectly to the immobilised capture binding agent.

Preferably, the marker is a fluorescent label, eg in the form of a large number (100 or more) of fluorescent dye molecules contained within microspheres having a size of
20 0.01 to 1 μm , eg 0.05 - 0.5 μm . It is preferred to use this technique in conjunction with the microspot technique already referred to, with the capture binding agent being immobilised as one or more microspots on a solid support at the surface densities and microspot sizes already mentioned
25 and optionally different capture binding agents being immobilised on different microspots on the same support to enable a plurality of different DNA sequences to be detected or determined in a single operation using appropriately differentiated developing binding materials and signal
30 detection or signal strength measurement techniques.

The procedures for forming a single-stranded DNA probe and immobilising it on a solid support are well known and described in the literature, and standard techniques can be used for this and for the formation of the liquid sample
35 containing the analyte (DNA sequence which may or may not be present) to be detected. Coupling of the developing binding

material to the microspheres may be carried out as mentioned above and the usual precautions to avoid contamination etc and other disturbing influences should be taken.

In a further embodiment the present invention provides
5 a kit for use in a binding assay process in which the concentration of an analyte in a liquid sample is determined using a capture binding agent having binding sites specific for the analyte and a developing binding material capable of binding with the bound analyte or with the binding sites on
10 the capture binding agent occupied by the bound analyte or with the binding sites remaining unoccupied on the capture binding agent, a label being used in relation to the developing binding material whereby the strength of the signal associated with the label is representative of the
15 fractional occupancy of the binding sites on the capture binding agent by the analyte, the kit comprising (a) a solid support having the capture binding agent immobilised thereon, (b) a developing reagent comprising the developing binding material adsorbed or directly or indirectly
20 chemically bonded to the surface of microspheres carrying a marker and (c) standards having known amounts or concentrations of the analyte to be determined.

Preferably, the developing reagent comprises a buffered solution containing the developing binding material
25 attached to the microspheres, but it is also possible to provide the reagent in freeze-dried form. Similarly, the standards may also be provided as buffered solutions containing the analyte at known concentrations or in freeze dried form with instructions for appropriate reconstitution
30 in solution form.

Preferably, the developing reagent contains the developing binding material adsorbed onto or covalently bonded to microspheres having a size of less than 5 μm and containing molecules of a fluorescent dye, and it is
35 preferred that the solid support has the capture binding

agent immobilised thereon in the form of one or more microspots of size less than 1 mm^2 and surface density at least 1000 IgG molecules/ μm^2 . Different capture binding agents may be immobilised on different microspots on the same solid support and a plurality of different developing reagents and different sets of standards may be provided so that a variety of different assays for different analytes may be performed using the same solid support in a single operation, simultaneously or sequentially.

10 The invention is further described in the following Examples, which illustrate the preparation of the labelled developing binding material and processes according to the invention.

In the Examples concentration percentages are by 15 weight.

Example 1

Adsorption of Antibody or Avidin on Hydrophobic Sulfate-Microspheres

20 1) 0.5 ml of 2% solids suspension in pure water of surfactant-free sulphate-activated microspheres of polymer latex materials containing fluorescent dye molecules within the microspheres (FluoSpheres from Molecular Probes Inc - FluoSpheres is a Registered Trade Mark) having a diameter 25 0.08 or $0.12\mu\text{m}$ was added dropwise to 2 mg of developing binding material (antibody or avidin) dissolved in 1 ml of 0.1 M phosphate buffer at pH 7.4. The suspension was shaken overnight at 4°C .

30 2) The suspension was centrifuged at 20,000 rpm for 30 min at 10°C (the time and speed of the centrifugation will vary with the size of the latex microspheres) to separate antibody-conjugated latex microspheres from unreacted antibody. The supernatant antibody or avidin solution was

recovered for protein estimation.

3) The centrifuged pellet was dispersed in 1.0 ml of 0.1 M phosphate buffer by sonication. After dispersion, the unoccupied hydrophobic sites on the microspheres were
5 blocked by the addition of 1 ml of 2% (1% final) bovine serum albumin (BSA) and shaken for 2 hours at room temperature. The spheres were further blocked by the addition of 200 μ l of 5% Tween-20 (~0.5% final) and shaken for 1 hour at room temperature. The detergent incubation
10 step also served to get rid of loosely bound antibody/avidin which might desorb into storage and/or assay buffer and would subsequently interfere with assays.

4) The preparation was centrifuged as above and the microspheres resuspended in 2 ml of 0.1 M phosphate buffer.

15 5) Step 4 was repeated twice. After the final centrifugation, the microspheres were dispersed in 2 ml of phosphate buffer containing 0.2% BSA and 0.01% sodium azide and stored at 4°C.

Example 2

20 Covalent Coupling of Antibody or Avidin to Carboxylate-Modified Latex Microspheres by a one-step method

1) 0.5 ml of a 2% solids suspension in pure material of carboxylate-modified polymer latex microspheres containing fluorescent dye molecules (FluoSpheres from Molecular Probes
25 Inc) and having a diameter of 0.09 μ m was added dropwise to 0.5 ml of 0.015 M, pH 5 acetate buffer containing 2 mg of antibody or avidin as developing binding material. The suspension was incubated at room temperature for 15 min.

2) 4 mg of EDAC [1-ethyl-3-(3-dimethylaminopropyl)-
30 carbodiimide] (Sigma Chemical Company) was added to the mixture and vortexed. The pH was adjusted to 6.5 \pm 0.2 with

dilute NaOH (agglomeration of the latex microspheres may be observed at this stage, but they can be redispersed by gentle sonication) and the reaction mixture was mixed gently overnight at 4°C.

5 3) The reaction mixture was centrifuged at 20,000 rpm for 30 min at 10°C. The supernatant was recovered for protein estimation.

4) The centrifuged pellet was dispersed in 1.0 ml of 0.1M phosphate buffer by sonication. After dispersion, the
10 unoccupied sites on the microspheres were blocked by the addition of 1 ml of 2% (1% final) bovine serum albumin (BSA) and shaken for 2 hours at room temperature. The spheres were further blocked by the addition of 200µl of 5% Tween-20 (~0.5% final) and shaken for a further 1 hour at room
15 temperature.

5) The preparation was centrifuged as above and the microspheres resuspended in 2 ml of 0.1M phosphate buffer.

6) Step 5 was repeated twice and, after the final centrifugation, the antibody- or avidin- conjugated
20 microspheres were dispersed in 2 ml of phosphate buffer containing 0.2% BSA and 0.01% of sodium azide and kept at 4°C.

Example 3

Covalent Coupling of an Antibody or Avidin to Carboxylate- 25 Modified Latex Microspheres by a two-step method

1) 0.5ml of the suspension of carboxylate-modified latex microspheres used in Example 2 was added to a 10 ml centrifuge tube and centrifuged at 20,000 rpm for 30 min at 10°C.

30 2) The centrifuged pellet was resuspended in 0.5ml of 0.02

M phosphate buffer, pH 4.5, and centrifuged as above.

3) Step 2 was repeated.

4) 0.5 ml of a 2% solution of EDAC was added dropwise to the dispersed microspheres (agglomeration of the latex
5 microspheres may be observed at this stage, but they can be redispersed by gentle sonication), and the reaction mixture was mixed gently at room temperature for 3 hours and centrifuged as above.

5) The centrifuged pellet was resuspended in 1 ml of 0.2 M
10 borate buffer, pH 8.5, and centrifuged as above.

6) Step 5 was repeated twice.

7) The centrifuged pellet was resuspended in 0.5 ml of borate buffer, added dropwise to 2 mg of antibody or avidin dissolved in 0.5 ml of the same buffer and mixed gently
15 overnight at room temperature.

8) The suspension was centrifuged as above and the supernatant was kept for protein estimation.

9) The centrifuged pellet was resuspended in 1 ml of 0.1M ethanolamine in borate buffer, mixed gently for 30 min at
20 room temperature and centrifuged as above.

10) The centrifuged pellet was resuspended in 1 ml of 1% BSA, mixed gently for 1 hour and centrifuged as above.

11) The centrifuged pellet was resuspended in 1 ml of 0.5% Tween-20, mixed gently for 1 hour and centrifuged as above.

25 12) The centrifuged pellet was resuspended in 1 ml of 0.02 M phosphate buffer, pH 7.4, and centrifuged as above.

13) The centrifuged pellet was resuspended in 1 ml of

phosphate buffer containing 0.2% BSA and 0.01% of sodium azide and kept at 4°C.

Example 4a

Coupling of a Mixture of Antibody and Avidin to Microspheres
5 by Adsorption or Covalent Linkage

The methodologies for the coupling of a mixture of antibody and avidin to microspheres by adsorption or covalent linkage were essentially the same as those described in Examples 1 to 3 above for the coupling of
10 antibody or avidin to microspheres except that the antibody solution used for the reaction also contained a small amount of avidin.

Example 4b

Labelling of a Monoclonal Anti-TSH Antibody with Texas Red

- 15 1) 1 mg of monoclonal anti-TSH antibody was dissolved in 1 ml of carbonate buffer pH 9.
- 2) 1 mg of Texas Red (Molecular Probes Inc.) was dissolved in 250 μ l of N,N-Dimethylformamide (Sigma Chemical Company), yielding a concentration of 4 μ g/ μ l.
- 20 3) 10 μ l of the 4 μ g/ μ l Texas Red was added to the antibody solution, vortexed and left on ice for two hours (dye to protein ratio (w/w) = 0.04).
- 4) The Texas Red-conjugated antibody was separated from unreacted and hydrolysed dye on a PD10 Sephadex column
25 (Pharmacia) by elution with 0.1M phosphate buffer, pH 7.4.
- 5) Sodium azide was added to the labelled antibody (0.1%) as preservative and the preparation was stored at 4°C.

Example 4c

Labelling of Antibody or BSA with Biotin

- 1) 2 mg of antibody or BSA was dissolved in 1 ml of pH 8.5 bicarbonate buffer.
- 5 2) 2.2 mg of N-Hydroxysuccinimidyl 6-(Biotinamido) Hexanoate (Vector Laboratories) was dissolved in 55 μ l of N,N-Dimethylformamide, yielding a concentration of 40 μ g/ μ l.
- 3) 10 μ l of the 40 μ g/ μ l biotin was added to the antibody or BSA solution and shaken for 2 hours at room temperature
- 10 (biotin to protein ratio (w/w) = 0.2).
- 4) The reaction was terminated by the addition of 10 mg of glycine.
- 5) The biotin-conjugated IgG or BSA was separated from unreacted biotin on a PD10 Sephadex column (Pharmacia) by
- 15 elution with 0.1M phosphate buffer, pH 7.4.
- 6) Sodium azide was added to the conjugated preparation (0.1%) which was stored at 4°C.

Example 5

An Ultra-sensitive Sandwich Two-step Back-titration TSH
20 Microspot Immunoassay employing Developing Antibody
Conjugated to Fluorescent Microspheres

First Step

- 1) White polystyrene microtitre wells (Microlite 1 from Dynatech Laboratories) were spotted with 1 μ l or less of a
- 25 200 μ g/ml monoclonal anti-TSH capture antibody in 0.1M phosphate buffer at pH 7.4. The antibody droplets were aspirated immediately and the wells blocked with 1% (w/v)

BSA and washed extensively with the same buffer. The antibody microspots were kept in buffer until use.

2) After rinsing with 0.05M/l Tris-HCl buffer at pH 7.75 (wash buffer), 200 μ l of either standard in assay buffer or the sample was added to each well and shaken for from 30 min to several hours at room temperature (or overnight at 4°C if maximal assay sensitivity is desired).

3) The wells were washed four times with wash buffer.

Second step

10 1) An aliquot of 200 μ l of developing binding material antibody conjugated to fluorescent-dye containing microspheres of diameter 0.1 μ m (containing ~0.01 mg antibody-conjugated microspheres) in assay buffer was added to each well and shaken for 0.5 to 1 hour at room
15 temperature.

2) The wells were washed seven times with the wash buffer which contained 0.05% Tween-20 (w/v), aspirated until completely dry and scanned with an MRC-600 Laser Scanning Confocal Microscope (Bio-Rad Microscience). The signal
20 emitted from each antibody microspot was quantified and the results were compared with the standard dose-response curve to determine TSH concentrations in unknown samples.

Example 6

An assay for thyroid stimulating hormone (TSH) was carried out using two monoclonal antibodies directed at different epitopes on the TSH molecule as capture and developing antibodies, and TSH standard samples supplied by the National Institute for Biological Standards and Control. The capture antibody was deposited as microspots approximately 0.5 mm in diameter on Dynatech Microlite microtitre wells by passive adsorption, giving a surface density of about 40,000 IgG molecules/ μm^2 . The developing antibody was covalently coupled to carboxylate-modified polystyrene latex FluoSpheres 0.08 μm in diameter containing yellow/green fluorescent dye. The TSH samples were applied to the microtitre wells in amounts of about 200 μl .

Following overnight incubation, the results obtained were as plotted on the accompanying Figure 3, which is a graph of fluorescence intensity (y-axis) in arbitrary units against TSH concentration (x-axis) in mU/litre. The sensitivity of the assay (based on measurements of the standard deviation of the zero dose estimate) was 0.002 mU/litre.

Example 7

Example 6 was repeated except that the total incubation time was reduced to 1 hour (0.5 hour incubation of sample with capture antibody, followed by 0.5 hour incubation with developing antibody) and the size of the microspheres was increased to 0.12 μm diameter. The sensitivity of the assay was thereby increased ten-fold to 0.0002 mU/litre, based on measurements of the standard deviation of the zero dose estimate. The results are plotted in the accompanying Figure 4 which is a graph on the same axes as Figure 3.

Example 8

A Single-step Ultra-sensitive Sandwich TSH Microspot Immunoassay Using Developing Antibody Conjugated to Fluorescent Microspheres

5 1) White polystyrene microtitre wells (Microlite 1 from Dynatech Laboratories) were spotted with 1 μ l or less of a 200 μ g/ml monoclonal anti-TSH capture antibody in 0.1 M phosphate buffer at pH 7.4. The antibody droplets were aspirated immediately and the wells blocked with 1% (w/v)
10 BSA and washed extensively with the same buffer. The antibody microspots were kept in buffer until use.

2) The wells were rinsed with assay buffer, then 100 μ l of standard in assay buffer/sample and 100 μ l of developing antibody-conjugated microspheres were added to each well and
15 shaken at room temperature for 30 minutes, or longer if maximal assay sensitivity was desired.

3) The wells were washed seven times with wash buffer containing 0.05% Tween-20 (w/v), aspirated until completely dry and scanned with the confocal microscope as in Example
20 5 above, the results being compared with the standard dose-response curve to determine the TSH concentration in unknown samples.

Example 9

Dual-labelled Ultra-sensitive Sandwich Single- or Two-step Back-titration TSH Microspot Immunoassay Using Developing Antibody Conjugated to Fluorescent Microspheres

The protocols for the dual-labelled single or two-step assays are essentially the same as those for the single labelled assays described above except the unlabelled
30 capture antibody is either labelled with Texas Red (Molecular Probes Inc.) and deposited directly on the white

Dynatech Microlite microtitre wells; or it can be coupled together with avidin to latex microspheres (Molecular Probes Inc) containing red fluorescent dye and the conjugated microspheres are then allowed to bind to a biotin-labelled BSA microspot deposited previously on the microtitre wells.

Example 10

A dual-label assay was carried out. The developing antibody was conjugated to yellow/green polystyrene latex microspheres of 0.12 μm diameter as described in Examples 1, 2 and 3. The capture antibody was deposited indirectly on Dynatech Microlite microtitre wells at a surface density of about 40,000 IgG molecules/ μm^2 via biotin/avidin. The antibody was first conjugated together with avidin to polystyrene latex microspheres of 0.1 μm diameter containing red fluorescent dye, the conjugated spheres then being allowed to bind to biotinylated BSA microspots previously coated on the microtitre wells. The yellow/green and orange/red dyes were scanned using the 488 and 568 nm lines of the krypton/argon mixed-gas laser. This could be done either simultaneously or consecutively. The concentration of antigen (TSH) in the test sample was obtained by observing the ratio of the fluorescent signals from the two dyes and correlating it with the signals using the standard samples.

The results obtained are shown in the accompanying Figure 5 which is a graph of the ratio of the two fluorescent signals (y-axis) against TSH concentration (x-axis) in mU/litre. The sensitivity of the assay (based on measurements of the standard deviation of the zero dose estimate) was 0.0002 mU/litre.

Example 11

Single-labelled or Dual-labelled Ultra-sensitive Sandwich
Single- or Two-step Back-titration TSH Microspot Immunoassay
Using Biotinylated Developing antibody and a Universal
5 Reagent of Avidin conjugated Fluorescent Microspheres

In contrast to the assay systems described in Examples 5 to 10, a universal marker reagent of avidin conjugated fluorescent microspheres was used in this Example to tag indirectly the bound developing antibody which had been 10 labelled with biotin.

Although this assay system requires an additional step of the addition of avidin microspheres after the completion of the immunological reactions, the advantage of being able to use a "universal marker" outweighs this minor drawback. 15 The "universal marker" system would be particularly useful in a microspot multianalyte system described by Roger Ekins in WO-89/01157 because of the considerable improvements in assay sensitivity that can be expected as a result of the reduction in non-specific binding from employing a single 20 universal avidin-microsphere preparation rather than the large number (equivalent to the number of simultaneous assays being performed) of developing antibody conjugated microsphere preparations that would otherwise be required.

The assay buffer composition in Examples 5-11 was:

25	Tris-(hydroxymethyl)-aminomethane	50 mM/l
	Sodium chloride	9.0 g/l
	Bovine serum albumin	5.0 g/l
	Bovine globulin	0.5 g/l
	Tween 40	0.1 g/l
30	Sodium azide	0.5 g/l
	HCl	to a pH of 7.75 at 25°C

Example 12

Microspot DNA Sequence Assay Methodologies

Non-competitive methodologies (qualitative and quantitative assays)

5

Example 12a

Microspot sandwich DNA sequence assay using a biotinylated solid-phased capture DNA probe and anti-double-stranded DNA antibody conjugated to microspheres containing fluorescent dye.

10 a) Microlite 1 microtitre wells were spotted with 1 μ l or less of 100 μ g/ μ l Avidin DX (Vector Laboratories) by adsorption for 1 hour at room temperature, blocked for 20 min with 200 μ l of 0.1 M Tris-HCl pH 7.5 containing 0.15 M NaCl, 0.05% Tween 20, 0.5% BSA and 100 μ g/ml salmon sperm
15 DNA and washed with Tris-HCl containing 0.05% Tween 20.

b) 5 to 100 ng of the biotinylated capture DNA probe in 100 μ l of Tris EDTA was added to the avidin DX coated wells, incubated with shaking for 2hr at room temperature and washed with Tris-HCl containing 0.05% Tween 20.

20 c) Samples were prepared by boiling 0.5ml aliquots for 10 min, then cooled rapidly on ice, diluted with hybridization buffer containing : 1X SSC (150 mmol/l of NaCl and 15mmol of trisodium citrate per litre), 2X Denhardt's solution (0.4 g of BSA, 0.4 g of Ficoll and 0.4 g of polyvinylpyrrolidone per
25 litre), 10mmol/l Tris-HCl pH7.5, and 1mmol/l EDTA. For a quantitative assay, the prepared samples and standards containing single-stranded target DNA and in the same hybridisation buffer were added to the wells (samples plus positive and negative controls were added for the
30 qualitative tests), incubated with shaking at 50°C for 1 hour and washed with PBS containing 0.05% Tween 20.

d) 200 μ l of anti-double-stranded DNA antibody conjugated to fluorescent microspheres of diameter 0.1 μ m (FluoSpheres) by the method described in Example 3 and in PBS containing 0.5% BSA and 0.05% Tween 20 was added, incubated with 5 shaking for 1 hour at room temperature, washed with PBS-Tween 20 and scanned with the confocal microscope as described in Example 5.

Example 12b

Microspot sandwich DNA sequence assay using a biotinylated 10 solid-phased capture DNA probe, a complementary but non-overlapping developing DNA probe labelled with digoxigenin and anti-digoxigenin antibody conjugated to microspheres containing fluorescent dye.

a) The avidin-biotinylated capture DNA probe microspots. 15 were prepared as described in Example 12a.

b) Samples were prepared by boiling 0.5ml aliquots for 10 min, then cooled rapidly on ice, diluted with hybridization buffer containing : 1X SSC (150mmol/l of NaCl and 15mmol of trisodium citrate per litre), 2X Denhardt's solution (0.4 g 20 of BSA, 0.4 g of Ficoll and 0.4 g of polyvinylpyrrolidone per litre), 10mmol/l Tris-HCl pH 7.5, and 1mmol/l EDTA. For a quantitative assay, the prepared samples and standards containing single-stranded target DNA and in the same hybridisation buffer were added to the wells (samples plus 25 positive and negative controls were added for the qualitative tests), incubated with shaking at 50°C for 1 hour and washed with Tris-HCl containing 0.05% Tween 20.

c) 5 to 10 ng of the complementary but non-overlapping developing DNA probe labelled with digoxigenin in 100 μ l of 30 hybridization buffer was added, incubated with shaking at 50°C for 1 hour and washed with PBS-Tween 20.

d) 200 μ l of the anti-digoxigenin antibody-conjugated

fluorescent microspheres of about 0.1 μm diameter (FluoSpheres) in PBS containing 0.5% BSA and 0.05% Tween 20 were added, incubated for 1 hour at room temperature with shaking, washed with PBS-Tween 20 and scanned with the
5 confocal microscope.

Example 12c

Microspot sandwich DNA sequence assay using an unlabelled solid-phased capture DNA probe and anti-double-stranded DNA
10 antibody conjugated to microspheres containing fluorescent dye

a) Microlite 1 microtitre wells were spotted with 1 μl or less of capture DNA probe by adsorption, blocked with salmon sperm DNA and washed with phosphate buffered saline
15 containing 0.1% Tween 20 (PBS-Tween 20).

b) For a quantitative assay, samples and standards containing single-stranded target DNA were added to the wells (samples plus positive and negative controls were added for the qualitative tests), incubated with shaking and
20 washed with PBS-Tween 20.

c) Anti-double-stranded DNA antibody conjugated to fluorescent microspheres of diameter 0.1 μm (FluoSpheres-Molecular Probes Inc) was added, incubated with shaking, washed with PBS-Tween 20 and scanned with the confocal
25 microscope as described in Example 5.

Example 12d

Microspot sandwich DNA sequence assay using an unlabelled solid-phased capture DNA probe, a complementary but non-overlapping biotinylated developing DNA developing probe and
30 avidin-conjugated microspheres containing fluorescent dye.

a) The capture DNA probe was spotted directly on the

microtitre wells as described in Example 12a above and washed with PBS-Tween 20.

b) For a quantitative assay, samples and standards containing single-stranded target DNA were added to the 5 wells (samples plus positive and negative controls were added for the qualitative tests), incubated with shaking and washed with PBS-Tween 20.

c) The biotinylated developing DNA probe was added, incubated with shaking and washed with PBS-Tween 20.

10 d) The avidin-conjugated fluorescent microspheres of diameter about 0.1 μm (FluoSpheres) were added, incubated and washed with PBS-Tween 20 and scanned with the confocal microscope.

Example 12e

15 Microspot sandwich DNA sequence assay using an unlabelled solid phased capture DNA probe, a complementary but non-overlapping developing DNA probe labelled with digoxigenin and antidigoxigenin antibody conjugated to microspheres containing fluorescent dye.

20 a) Capture DNA probe microspots were prepared as described in Example 12a.

b) For a quantitative assay, samples and standards containing single-stranded target DNA were added to the wells (samples plus positive and negative controls were 25 added for the qualitative tests), incubated with shaking and washed with PBS-Tween 20.

c) The complementary but non-overlapping developing DNA probe labelled with digoxigenin was added, incubated with shaking and washed with PBS-Tween 20.

d) The anti-digoxigenin antibody-conjugated fluorescent microspheres of diameter about 0.1 μm (FluoSpheres) were added, incubated with shaking, washed and scanned with the confocal microscope.

5 Competitive DNA sequence assay methodologies (quantitative)

Example 12f

Competitive microspot DNA sequence assay using an unlabelled solid-phased capture DNA probe, a biotinylated developing target DNA probe and avidin-conjugated fluorescent
10 microspheres.

a) Capture DNA probe microspots were prepared as described in Example 12a.

b) Samples and standards containing single-stranded target DNA and biotinylated target DNA probes were added, incubated
15 with shaking and washed with PBS-Tween 20.

c) Avidin-conjugated fluorescent microspheres of about 0.1 μm diameter (FluoSpheres) were added, incubated with shaking, washed with PBS-Tween 20 and scanned with the confocal microscope.

20

Example 12g

Competitive Microspot DNA sequence assay using a biotinylated solid-phased capture DNA probe and developing target DNA probe conjugated to fluorescent microspheres.

a) The avidin-biotinylated capture DNA probe microspots
25 were prepared as described in Example 12b.

b) Samples and standards containing single-stranded target DNA and target DNA probes conjugated to fluorescent microspheres of about 0.1 μm diameter (FluoSpheres) were

added, incubated with shaking, washed with PBS-Tween 20 and scanned with the confocal microscope.

As indicated above, these very high sensitivities for non-competitive immunoassays are unexpected in the light of the currently accepted views on assay design. Some increase in sensitivity would be expected in any assay format, once the idea of using microspheres in accordance with the invention has been appreciated, because of the increased number of molecules of label attached to each molecule of developing binding material, this resulting in an effective increase in specific activity of the labelled developer molecules. However, this effect alone would not be expected to result in assay designs departing so markedly from conventional concepts in this field and requiring in particular very small amounts of capture binding agent.

Two possible explanations for these unexpected findings can perhaps be advanced. The first is that by confining a very small number of capture binding agent molecules at high surface density to a very small area in the form of a microspot the signal/noise ratios obtained in any finite incubation time may be improved as compared with those obtained in conventional designs in which very large amounts of capture antibody are distributed over large surface areas. The second is that when analyte molecules are located between two solid surfaces on which the capture binding agent and developing binding material molecules are respectively located (viz the microspheres and the microtitre wells in which the assay is performed) binding sites on the analyte molecules may become bound to multiple developing binding material molecules if the analyte contains the same epitope replicated on its surface or if the developing binding material is a polyclonal antibody or if more than one monoclonal antibody directed at different epitopes on the analyte is used as developing material, thus increasing the effective affinity of the developing binding material. This implies that the surface density of

- 34 -

developing binding material molecules on the microspheres is likely to represent an important determinant of the sensitivities achieved.

CLAIMS

1. A binding assay process in which the concentration of an analyte in a liquid sample is determined by comparison with a dose-response curve computed from standard samples,
5 using a capture binding agent having binding sites specific for the analyte and a developing binding material capable of binding with the bound analyte or with the binding sites on the capture binding agent occupied by the bound analyte or with the binding sites remaining unoccupied
10 on the capture binding agent,

the capture binding agent being used in an amount such that only an insignificant fraction of the analyte in the sample becomes bound to the capture binding agent, and

a label being used in the assay in relation to the
15 developing binding material whereby the strength of the signal associated with the label is representative of the fractional occupancy of the binding sites on the capture binding agent by the analyte,

wherein there is used as the label microspheres having
20 a size of less than 5 μm and carrying a marker.

2. A process as claimed in claim 1, wherein the microspheres have a uniform size of 0.01 to 0.5 μm .

3. A process as claimed in claim 1 or 2, wherein the microspheres are made of polymer latex and are provided on
25 their surface with negatively charged or positively charged groups.

4. A process as claimed in any of claims 1 to 3, wherein the marker is a fluorescent label contained within the microspheres.

30 5. A process as claimed in claim 4, wherein the microspheres contain molecules of an oil-soluble fluorescent dye providing fluorescence in a colour range compatible with

a standard filter set.

6. A process as claimed in claim 4, wherein the microspheres contain molecules of a fluorescent dye having a prolonged fluorescent period such that the signal strength is capable of being determined by a time-resolved fluorescence technique.

7. A process as claimed in any of claims 1 to 6, wherein the microspheres have the developing binding material adsorbed or directly or indirectly chemically bonded to them.

8. A process as claimed in any of claims 1 to 6, wherein some of the microspheres have the developing binding material adsorbed or directly or indirectly chemically bonded to them and others of the microspheres have the capture binding agent adsorbed or directly or indirectly chemically bonded to them, the label contained in the microspheres to which the developing binding material is adsorbed or chemically bonded being different from the label in the microspheres to which the capture binding agent is adsorbed or chemically bonded.

9. A process as claimed in claim 7 or 8, wherein, after the developing binding material and where appropriate the capture binding agent have been linked to the microspheres by adsorption or covalent bonding, the microspheres are blocked to avoid their non-specific binding to other materials.

10. A process as claimed in claim 9, wherein the blocking of the microspheres is achieved by means of bovine serum albumin or other non-interfering protein material and a non-ionic detergent.

11. A process as claimed in any of claims 1 to 10,

wherein the capture binding agent is immobilised on a solid support in the form of one or more microspots having an area of 1 mm^2 or less at a surface density in the range of 1,000 to 100,000 IgG molecules/ μm^2 , and wherein the liquid sample size is 1 ml or less.

12. A process as claimed in claim 11, wherein the microspot or microspots have a diameter of 0.01 to 1 mm and contain immobilised capture binding agent at a surface density of 10,000 to 50,000 IgG molecules/ μm^2 , the sample size being 50 μl - 1 ml.

13. A process as claimed in claim 11 or 12, wherein different capture binding agents are immobilised on different microspots on the same solid support and different binding assays for the determination of different analytes in the same liquid sample are performed in the same operation.

14. A process as claimed in any of claims 1 to 13, wherein both the capture binding agent and the developing binding material are antibodies.

15. A process as claimed in any of claims 1 to 13, for use in DNA assays, wherein the capture binding agent is a single-stranded oligonucleotide DNA probe recognising a corresponding DNA sequence in the liquid sample and the developing binding material either is an antibody recognising only twin-stranded DNA sequences or is an oligonucleotide DNA sequence which either recognises another part of the corresponding DNA sequence in the liquid sample or recognises residual single-stranded oligonucleotide DNA probe forming the capture binding agent, the developing binding material being labelled by means of the microspheres.

16. A process as claimed in any of claims 1 to 15, wherein the binding assay is a non-competitive binding

assay.

17. A binding assay process for the detection of an analyte comprising a single-stranded DNA sequence in a liquid sample, comprising

5 contacting the sample in a non-competitive or competitive procedure with

 an immobilised capture binding agent which is a single-stranded oligonucleotide DNA probe capable of recognising analyte in the liquid sample and binding
10 therewith, and

 with a labelled developing binding material which either is an antibody capable of recognising only twin-stranded DNA sequences formed from the probe and the analyte and of binding therewith or is an oligonucleotide DNA
15 sequence capable of recognising and binding with either another part of the analyte or the residual probe,

 the developing binding material being labelled by means of microspheres having a size of less than 5 μ m and carrying a marker, and,

20 after the removal of unattached developing binding material, detecting the presence of the analyte by the existence or strength of a signal from the marker attached to developing binding material which has become bonded directly or indirectly to the immobilised capture binding
25 agent.

18. A process as claimed in claim 17, wherein the marker is a fluorescent label contained within microspheres having a size of 0.01 to 1 μ m.

19. A process as claimed in claim 17 or 18, wherein
30 the developing binding material is directly or indirectly covalently bonded to the microspheres.

20. A kit for use in a binding assay process in which the concentration of an analyte in a liquid sample is determined using a capture binding agent having binding

sites specific for the analyte and a developing binding material capable of binding with the bound analyte or with the binding sites on the capture binding agent occupied by the bound analyte or with the binding sites remaining
5 unoccupied on the capture binding agent, a label being used in relation to the developing binding material whereby the strength of the signal associated with the label is representative of the fractional occupancy of the binding sites on the capture binding agent by the analyte, the kit
10 comprising (a) a solid support having the capture binding agent immobilised thereon, (b) a developing reagent comprising the developing binding material adsorbed or directly or indirectly chemically bonded to the surface of microspheres carrying a marker and (c) standards having
15 known amounts or concentrations of the analyte to be determined.

21. A kit as claimed in claim 20, wherein the reagent contains the developing binding material adsorbed onto or covalently bonded to microspheres having a size of less than
20 5 μm and containing molecules of a fluorescent dye.

22. A kit as claimed in claim 20 or 21, wherein the solid support has the capture binding agent immobilised thereon in the form of one or more microspots of size less than 1 mm^2 and surface density at least 1000 IgG molecules/
25 μm^2 .

23. A kit as claimed in claim 22, wherein different capture binding agents are immobilised on different microspots on the same solid support and a plurality of different developing reagents and different standards for
30 different analytes are included.

THIS PAGE BLANK (USPTO)

Fig. 1




Fig. 2


1 cm

0.1 mm

1 mm

$d = 0.1$
 $[Ab] = 0.001/K$
 $s/n = 100\%$

$d = 1.0$
 $[Ab] = 0.1/K$
 $s/n = 90.9\%$



$d = 10.0$
 $[Ab] = 10/K$
 $s/n = 9.09\%$

THIS PAGE BLANK (USPTO)

Fig. 3






Fig. 4



THIS PAGE BLANK (USPTO)

Fig. 5



THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)